ECMO patients may get safer blood thinner in new trial

NCT ID NCT06275555

Recruiting now Disease control Sponsor: Xiaotong Hou Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether bivalirudin, a newer blood thinner, is safer and more effective than the standard drug heparin for patients on ECMO (a machine that helps the heart and lungs). The trial will enroll 154 adults on ECMO and track how many develop dangerous clots or bleeding. If bivalirudin proves better, it could improve outcomes for critically ill patients needing this advanced life support.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: bivalirudin
What this could lead to: If bivalirudin works better, it could reduce dangerous clots and bleeding for people on ECMO, making this life-saving support safer.
What could go wrong: This is a relatively small trial (154 people) and results may not apply to all ECMO patients. Both drugs carry bleeding risks, and bivalirudin may not prove superior.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for EXTRACORPOREAL MEMBRANE OXYGENATION COMPLICATION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

EXTRACORPOREAL MEMBRANE OXYGENATION COMPLICATION

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Beijing Anzhen Hospital
RECRUITING

Beijing, Beijing Municipality, 100029, China

Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.